[Oral osteoporosis: a review and its dental implications].
In post-menopausal osteoporosis, lack of estrogen will affect the remodeling of the bone tissue in such a way that, in most patients with periodontitis, the amount of bone resorbed exceeds that being formed, resulting in net bone loss. Osteoporosis can be treated by a variety of methods, the hormone replacement therapy (HRT), the selective estrogen receptor modulators (SERM) and the bisphosphonates. The HRT or bisphosphonates treatments improve the clinical outcome of periodontal disease and may be an adjunctive treatment to preserve periodontal bone mass. This paper reviews the current evidence on the mechanism of periodontal breakdown after menopause and the benefit to oral health by treatments for osteoporosis.
Inagaki
Koji
K
Aichi-Gakuin University, School of Dentistry, Department of Periodontology.
Kurosu
Yasunari
Y
Sakano
Masahiro
M
Yamamoto
Genta
G
Kikuchi
Takeshi
T
Noguchi
Toshihide
T
Yano
Hiroyasu
H
Izawa
Hiroyuki
H
Hachiya
Yudo
Y
D016301:Alveolar Bone Loss / Q000517:prevention & control*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004164:Diphosphonates / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000172:deficiency / Q000502:physiology; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications* / Q000188:drug therapy*; D010510:Periodontal Diseases / Q000209:etiology* / Q000517:prevention & control; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D004967:Estrogens; D020845:Selective Estrogen Receptor Modulators